The health plan star ratings have come under fire for not including more outcomes measures. Do these measurements reflect the outcomes that matter most to improving care?
November is National Diabetes Month, an appropriate time to explore why the nation's response to this growing, obesity-driven scourge deserves a grade of F.
The Trump administration has done everything possible short of repealing the Affordable Care Act to discourage Americans from signing up for health insurance coverage. No one should be surprised if 2018 enrollment falls short of last year.
Special interests and lobbyists are undermining the campaign to combat opioid abuse, an epidemic that is now taking the lives of nearly 100 Americans a day.
The Puerto Rican healthcare system, which serves the 3.4 million people devastated by Hurricane Maria, operates under patently unfair Medicaid and Medicare funding rules.
Dr. Price resigns, Las Vegas endures a massacre, Trump accuses Puerto Rican officials of playing politics, and its easy to think there is nothing to be done, but that is not true.
More and more of you are faced with the reality that you can't grow and you may not be able to fulfill your own missions without answering the call to change. Innovation no longer is a novelty; it's a necessity.
The U.S. over the last half century has moved inexorably toward universal coverage: Medicare and Medicaid; the Children's Health Insurance Program; the ACA. It will get there one way or another.
Don't kid yourself. We haven't heard the last of repealing and replacing Obamacare.
As patient satisfaction and well-being become more intimately tied to the performance of healthcare organizations, leaders would be smart to listen to employees and become personally invested in their advancement.
The pace of mergers and escalating concentration in both provider and insurance markets shows no sign of abating. The idea that antitrust can reverse this trend-or should-is misplaced.
Gilead Sciences has a knack for putting itself at the center of the drug pricing debate, this time with its new non-Hodgkin Lyphoma treatment that will cost over $500,000.